- Home
- IMRX vs SLS Comparison
IMRX vs SLS Comparison
Compare IMRX & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMRX
- SLS
- Stock Information
- Founded
- IMRX 2008
- SLS 2012
- Country
- IMRX United States
- SLS United States
- Employees
- IMRX N/A
- SLS N/A
- Industry
- IMRX Biotechnology: Pharmaceutical Preparations
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- IMRX Health Care
- SLS Health Care
- Exchange
- IMRX Nasdaq
- SLS Nasdaq
- Market Cap
- IMRX 73.2M
- SLS 75.3M
- IPO Year
- IMRX 2021
- SLS N/A
- Fundamental
- Price
- IMRX $1.94
- SLS $1.34
- Analyst Decision
- IMRX Buy
- SLS Buy
- Analyst Count
- IMRX 7
- SLS 1
- Target Price
- IMRX $12.60
- SLS $3.00
- AVG Volume (30 Days)
- IMRX 369.8K
- SLS 719.9K
- Earning Date
- IMRX 11-13-2024
- SLS 11-13-2024
- Dividend Yield
- IMRX N/A
- SLS N/A
- EPS Growth
- IMRX N/A
- SLS N/A
- EPS
- IMRX N/A
- SLS N/A
- Revenue
- IMRX N/A
- SLS N/A
- Revenue This Year
- IMRX N/A
- SLS N/A
- Revenue Next Year
- IMRX N/A
- SLS N/A
- P/E Ratio
- IMRX N/A
- SLS N/A
- Revenue Growth
- IMRX N/A
- SLS N/A
- 52 Week Low
- IMRX $1.00
- SLS $0.50
- 52 Week High
- IMRX $8.89
- SLS $1.72
- Technical
- Relative Strength Index (RSI)
- IMRX 51.04
- SLS 54.24
- Support Level
- IMRX $1.68
- SLS $1.07
- Resistance Level
- IMRX $1.97
- SLS $1.39
- Average True Range (ATR)
- IMRX 0.13
- SLS 0.07
- MACD
- IMRX -0.01
- SLS 0.01
- Stochastic Oscillator
- IMRX 71.72
- SLS 48.00
About IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.